DeepMed Research

Devimistat

Generic Name: Devimistat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈O_₂S_₂

CAS Number: 95809-78-2

Unique Ingredient Identifier: E76113IR49

Background: Devimistat (CPI-613) has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.

Clinical Trials

Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

Phase 1

Withdrawn

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Devimistat
Drug: Modified FOLFIRINOX

First Posted Date: 2023-07-03

Last Posted Date: 2023-08-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT05926206

Locations: 🇺🇸
Rogel Cancer Center, Ann Arbor, Michigan, United States

CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 2

Not yet recruiting

Conditions: Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
Granulocytic Sarcoma

Interventions: Drug: CPI 613
Drug: Metformin
Biological: Blood draws
Procedure: Bone marrow biopsy

First Posted Date: 2023-05-11

Last Posted Date: 2024-08-07

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 17

Registration Number: NCT05854966

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Phase 2

Recruiting

Conditions: Advanced Pancreatic Carcinoma
Metastatic Ovarian Carcinoma
Refractory Lung Adenocarcinoma
Refractory Urothelial Carcinoma
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Biliary Tract Carcinoma
Advanced Lung Adenocarcinoma
Advanced Malignant Solid Neoplasm
Advanced Urothelial Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Devimistat
Drug: Fluorouracil
Drug: Gemcitabine Hydrochloride
Drug: Hydroxychloroquine
Procedure: Magnetic Resonance Imaging

First Posted Date: 2023-02-17

Last Posted Date: 2023-03-10

Lead Sponsor: Northwestern University

Target Recruit Count: 94

Registration Number: NCT05733000

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Phase 1

Withdrawn

Conditions: C04.588.274.476.411.307

Interventions: Drug: CPI-613
Drug: modified FFX
Drug: Bevacizumab

First Posted Date: 2021-10-06

Last Posted Date: 2023-09-13

Lead Sponsor: Cornerstone Pharmaceuticals

Registration Number: NCT05070104

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Relapsed T-Cell Lymphoma
Refractory T-Cell Lymphoma
Non Hodgkin Lymphoma

Interventions: Drug: CPI 613
Drug: Bendamustine

First Posted Date: 2020-01-03

Last Posted Date: 2025-05-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 6

Registration Number: NCT04217317

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: CPI 613
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2019-12-18

Last Posted Date: 2024-07-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 75

Registration Number: NCT04203160

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University Hospitals - Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
Northwestern University -- Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

and more 7 locations

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Phase 1

Withdrawn

Conditions: Myelodysplastic Syndromes
Progressive Disease

Interventions: Drug: CPI-613
Drug: Hydroxychloroquine

First Posted Date: 2019-04-26

Last Posted Date: 2021-04-14

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT03929211

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Phase 2

Active, not recruiting

Conditions: Lymphoma
Leukemia

Interventions: Drug: CPI-613

First Posted Date: 2019-01-04

Last Posted Date: 2025-04-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT03793140

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

and more 8 locations

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: CPI 613
Drug: Oxaliplatin
Drug: Irinotecan
Drug: 5-flurouracil
Drug: Folinic acid

First Posted Date: 2018-10-09

Last Posted Date: 2025-01-23

Lead Sponsor: David Bajor, MD

Target Recruit Count: 49

Registration Number: NCT03699319

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Phase 2

Withdrawn

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: CPI-613
Drug: mFOLFIRNOX

First Posted Date: 2017-12-15

Last Posted Date: 2025-04-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT03374852

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy